课题基金 / 基金详情

Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD

Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD
定义干扰素-ε作为治疗哮喘和慢性阻塞性肺病流感的新疗法的作用并靶向干扰素-ε
批准号:
nhmrc : GNT1138004
负责人:
A/Pr Aeron Hurt
金额:
$90.59万
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2018
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2018-01-01 至 --

项目摘要

项目成果

A/Pr Aeron Hurt的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Influenza is a major cause of illness and death, especially in people with asthma and emphysema. There are issues with vaccines and current treatments are poorly effective. Effective treatments are urgently required. We have found a new immune factor, interferon-epsilon that is induced and used by influenza viruses to cause infection. We aim to understand how this occurs and to test new treatments for influenza that suppress interferon-epsilon, in healthy and susceptible individuals.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Defining the roles and targeting interferon-epsilon as a new therapy for influenza in asthma and COPD
  • 批准号:
    nhmrc : 1138004
  • 项目类别:
    Project Grants
  • 资助金额:
    $61.25万
  • 财政年份:
    2018
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Low-Cost Portable Inhalation Therapy Platform for Needle-Free DNA-Based Influenza Vaccination
  • 批准号:
    nhmrc : GNT1112870
  • 项目类别:
    Development Grants
  • 资助金额:
    $52.46万
  • 财政年份:
    2016
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Low-Cost Portable Inhalation Therapy Platform for Needle-Free DNA-Based Influenza Vaccination
  • 批准号:
    nhmrc : 1112870
  • 项目类别:
    Development Grants
  • 资助金额:
    $36.0万
  • 财政年份:
    2016
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
Determining the clinical effectiveness of antiviral drugs against oseltamivir- and laninamivir-resistant influenza viruses in animal models
  • 批准号:
    nhmrc : 1055793
  • 项目类别:
    Targeted Calls
  • 资助金额:
    $25.88万
  • 财政年份:
    2013
  • 负责人:
    A/Pr Aeron Hurt
  • 依托单位:
海外基金